leadf
logo-loader
viewAmryt Pharma PLC
(
AIM:AMYTNASDAQ:AMYTFRA:3N9
)

Amryt Pharma raises $40M in private placement from new and existing specialist biotech investors

Amryt Pharma PLC (NASDAQ:AMYT) (LON:AMYT) CEO Joe Wiley tells Proactive the group has raised $40M from leading biotech investors in a private placement, with a tranche of the proceeds being used to in-license or invest in rare disease technologies.

Wiley says investors include Stonepine Capital, Aquilo Capital Management, Amati Global Investors, Athyrium Capital Management, and Highbridge Capital Management. What's more, the firm has received marketing approval from the authorities in Brazil for its specialist cholesterol drug Lojuxta.

Quick facts: Amryt Pharma PLC

Follow
AIM:AMYT

Price: 180 GBX

Market Cap: £569.69 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Amryt reports record 2Q results and raises full-year guidance as momentum...

Amryt Pharma PLC (AIM:AMYT, NASDAQ:AMYT, FRA:3N9) CEO Joey Wiley joined Proactive’s Stephen Gunnion to discuss the company's second-quarter results, which show a 35.9% rise in revenue year-on-year. Wiley noting that it's the sixth consecutive quarter the company has reported positive EBITDA...

on 6/8/21

2 min read